Safety and Tolerability of REGN17235 in Adult Participants With Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome With SF3B1 Mutation

Clinical trial NCT07753148 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07753148
Sponsor: Regeneron Pharmaceuticals
Status: NOT_YET_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Clonal Cytopenia of Undetermined Significance (CCUS)Low-Risk Myelodysplastic Syndrome (LR-MDS)

Start date: 2026-09-17
Primary completion: 2031-05-05
Enrollment: 52

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.